Objectives-Heat-shock protein 90 (Hsp90) coordinates the regulation of diverse signaling proteins. We try to develop a new tool to explore the regulatory functions of Hsp90 in endothelial cells (ECs) instead of the existing chemical approaches. Methods and Results-We designed a dominant-negative Hsp90 construct by site-direct mutagenesis of residue to Asn (D88N-Hsp90) based on the structure of the ATP/ADP-binding site. Recombinant wild-type Hsp90 protein binds ATP-Sepharose beads in manner inhibited by ATP or 17-AAG, a specific inhibitor for Hsp90, however the binding activity of D88N-Hsp90 was markedly reduced and the inhibitory effects of ATP or 17-AAG were negligible. The dimerization between endogenous Hsp90␣ and exogenous HA-Hsp90␤ was confirmed by immunoprecipitation, however the association between eNOS and D88N-Hsp90 was less than WT-Hsp90. Furthermore, adenoviral transduction of bovine aortic ECs with D88N-Hsp90 suppressed VEGF-induced phosphorylation of Akt, eNOS, and NO release and the inhibitory effect was blocked by okadaic acid. Moreover, D88N-Hsp90 abolished VEGF-stimulated Rac activation and suppressed VEGF-induced stress fiber formation. 
H eat shock protein 90 (Hsp90) is an abundant and ubiquitous molecular chaperone that is involved in maintaining appropriate folding and conformational maturation of other proteins. 1 Apart from its cochaperones, Hsp90 is known to interact with a number of signaling molecules, including steroid hormone receptors, v-Src, Raf1, Akt, and NOS, and regulate cell signaling and functions. [2] [3] [4] This superchaperone complex formation cycles between 2 major conformations: the "open" state and "closed" state. In the "open" state, a client protein is loaded onto Hsp90 with the help of the cochaperones, such as Hsp70, Hsp40, Hop, and Hip. On ATP binding and hydrolysis, the complex switches to the "closed" state in which Cdc37, p23, and immunophilins replace the original cochaperones to assist with the conformational maturation of the client proteins and maintain these client proteins in an active state to exert their functions. 5 Blocking the ATP-binding site of Hsp90 by inhibitors such as geldanamycin (GA) locks the complex in the "open" state and ultimately results in degradation of some client proteins via an ubiquitin-proteasome-dependent pathway. 2 
See page 6
Hsp90 exists mainly as a constitutive homodimer, but it may be found as a monomer, as a heterodimer (consisting of ␣ and ␤ isoforms), or as a higher molecular weight oligomer in mammalian cells, 6, 7 and its dimerization domain resides mainly within the carboxyl-terminal 90 amino acids. Both Hsp90 ␣ and ␤ have a highly conserved 25 kDa N-terminal domain that is the ATP-binding pocket and binding site for GA. 8, 9 ATP binding assists in the dimerization of Hsp90 by changing its conformation and stabilizing Hsp90 client proteins. 8, 10 Substrate binding at the N-terminal site is affected by nucleotides (ATP and ADP) and by drugs such as GA. GA binds to Hsp90 and disrupts the complex between Hsp90 and certain client proteins such as the protein kinase Akt. 11 Structural studies of the ATP/ADP binding site in Hsp90 have shown that the only carboxyl side chain of Asp79 (D79) in yeast Hsp82 or Asp93 (D93) in human Hsp90␣ makes a direct hydrogen bond to the exocyclic N6 group of adenine of bound ATP/ADP nucleotide or the carbamate nitrogen of GA, 5, 12, 13 respectively. Site-directed mutagenesis of Asp97 to asparagine (D93N) in Hsp90␣ resulted in loss of ATP-binding activity and impaired ATP hydrolysis. Mutations of D79 in yeast Hsp82 to Asn, Arg, or Trp also abolished ATPase activity and yeast growth, suggesting that this conserved Asp residue is necessary for ATP/ADP binding and the function of Hsp90. 14, 15 Recent work has shown that Hsp90 coordinates the trafficking and regulation of diverse signaling proteins in endo-thelial cells (ECs). Previous studies have shown that stimulation of ECs with vascular endothelial growth factor (VEGF) recruits eNOS and Akt to the structurally flexible 35-kDa middle domain of Hsp90, which is separated from the N-terminal ATP/ADP binding domain by a divergent charged sequence, 16, 17 thereby facilitating eNOS phosphorylation and enzyme activation and nitric oxide (NO) release. 18 Because Hsp 90 can serves as a general molecular scaffold for signaling in endothelial cells, the central goal of this paper was to develop a mutant form of Hsp90␤ lacking the conserved Asp in the ATP-binding domain (D88 in Hsp90␤) and to generate an adenovirus to assess if overexpression of mutant Hsp90 influences endothelial cell functions in vitro.
Materials and Methods

Cell Culture and Reagents
Mouse lung endothelial cells (MLECs) were isolated from 3-weekold Akt1
Ϫ/Ϫ and WT mice as previously described. 22 Cells were propagated in EGM-2 media supplemented with EGM-2 microvascular (MV) SingleQuots (Cambrex).
Site-Direct Mutagenesis and Plasmid Construction
A single amino acid mutation (D88N) was generated in the Hsp90␤ using the QuickChange site-directed mutagenesis kit (Stratagene) with a primer (AACGTACCCTGACTTTGGT TAACACAGGCAT-TGGCATGAC) and confirmed by sequencing.
ATP-Sepharose Binding Assay
The ATP-Sepharose binding assay was performed using ␥-phosphate-linked ATP-Sepharose resin (Upstate Biotechnologies) and purified Hsp90 protein. Bound protein was eluted from the resin by boiling in SDS sample buffer for subsequent SDS-PAGE and Western blotting using Anti-Hsp90␤ antibody.
NO Release Assay
The serum-free media were processed for the measurement of nitrite NO 2 Ϫ , a stable breakdown product of NO in aqueous solution, using a Sievers NO chemiluminescence detector system as previously described. 18, 22 
Rac Activity Assay
Pull-down of GTP-bound Rac was performed by incubating cell lysates with GST-fusion protein containing the p21-binding domain of PAK-1 bound to glutathione agarose for 1 hour at 4°C. The amount of GTP-bound Rac was examined by immunoblotting using a Rac monoclonal antibody (BD Transduction Laboratories).
Phalloidin Staining
Cells were fixed with 2% formaldehyde and permeabilized with 0.1% Triton X-100 in phosphate buffered saline, pH7.5. F-actin was examined using Alex 568-conjugated phalloidin (Invitrogen).
Migration Assay
The transwell inserts (Costar transwell inserts; Corning) were coated with 0.1% gelatin (Sigma). VEGF at 50 ng/mL (1.1 nmol/L) dissolved in EBM-2 medium containing 0.1% bovine serum albumin (BSA) was added in the bottom chamber of Boyden apparatus. of bovine aortic endothelial cells (BAECs) or murine lung endothelial cells (MLECs; 2ϫ10 5 cells) suspended in 100 L aliquot of EBM-2 (Cambrex) containing 0.1% BSA was added to the upper chamber. After 5 hours incubation, cells on both sides of the membrane were fixed and stained with Diff-Quik staining kit (Baxter Healthcare Corp). The average number of cells from five randomly chosen high power (400ϫ) fields on the lower side of the membrane was counted.
For further details, see the supplemental materials. Figure 1C ). These data demonstrate that mutation of D88 to N disrupts the ATP binding capacity of Hsp90␤.
Dimerization of Mutant Hsp90 With Endogenous Hsp90 and Complex Formation of eNOS and Akt With Hsp90
Because Hsp90 plays an important role in regulating aspects of EC function, we generated adenoviruses to efficiently infect endothelial cells with cDNAs encoding GFP alone (as a control; Ad-GFP), HA tagged WT Hsp90 (Ad-Hsp90␤), or D88N Hsp90 (Ad-D88N Hsp90␤). The shuttle vectors for WT and D88N Hsp90 also expressed GFP. Primary cultures of BAECs were infected with different MOI of Ad-GFP or Ad-D88N and the expression of GFP and D88N-Hsp90␤ mutant was examined by Western blotting using antibodies against GFP and the HA epitope tag, respectively (supplemental Figure IA , available online at http://atvb.ahajournals. org). The results show that Ad-GFP and Ad-D88N achieved identical viral infectivity and expression as confirmed by GFP expression and D88N Hsp90␤. To examine whether point mutation in ATP-binding domain influenced the dimerization of expressed Hsp90 with endogenous Hsp90, BAECs were infected with Ad-GFP (control), Ad-Hsp90␤ WT, and Ad-D88N, and HA-tagged proteins were immunoprecipiated. As seen in supplemental Figure 1B, Figure IC ).
Dominant-Negative Hsp90␤ (D88N) Inhibits VEGF-Stimulated Phosphorylation of Akt and eNOS, and NO Production
To evaluate the effects of dominant-negative Hsp90␤ on VEGF-stimulated signaling in endothelial cells, BAECs were noninfected or infected with Ad-GFP or Ad-D88N Hsp90, then stimulated with VEGF (15 minutes), and the phosphorylation of Akt (on S473) and eNOS (on S1179) was examined by Western blotting. Figure 2A shows that D88N Hsp90 reduced the VEGF-stimulated phosphorylation levels of eNOS on serine 1179 and to a lesser extent Akt on serine 473 (as quantified in Figure 2B ) in total cell lysates. However, D88N Hsp90 had no effect on the basal phosphorylation levels of eNOS (S1179) or Akt (S473) (quantified in Figure  2B ; nϭ3 experiments). The changes in VEGF phosphorylation of eNOS and Akt were not attributable to changes in the levels of these proteins in the total cell lysates ( Figure 2C ). Figure 2C also shows the expression levels of exogenous HA-Hsp90␤-D88N from adenoviral infections are the similar to the levels of endogenous Hsp90␤ (Ad-GFP, 48.86Ϯ3.87 versus Ad-D88N, 91.32Ϯ5.72; PϽ0.01). Next, we examined VEGF-stimulated NO production in BAECs noninfected or infected with Ad-GFP or Ad-D88N Hsp90␤. Infection of BAECs with Ad-D88N Hsp90 or Ad-GFP had no significant inhibitory effects on the basal NO production ( Figure 2D , assessed as the stable product nitrite, NO 2 Ϫ ), whereas VEGFstimulated NO production was reduced by infection with D88N Hsp90 compared with control and Ad-GFP infected cells ( Figure 3D ).
There is evidence that Hsp90 interacts with Akt and preserves Akt activity by preventing its dephosphorylation on S473 by the phosphatase PP2A. 11 Infection of BAECs with Ad-D88N Hsp90, but not Ad-GFP, reduced VEGF-induced Akt phosphorylation consistent with previous data using GA, 8 and the dephosphorylation of Akt S473 was blocked by treatment of cells with okadaic acid (500 nmol/L), a PP2A inhibitor ( Figure 3A and as quantified in Figure 3B ). Ad-D88N Hsp90 did not show any effect on the basal activation of Akt ( Figure 3A and as quantified in Figure 3B ). 
D88NHsp90␤ Suppresses VEGF-Stimulated EC Migration
Hsp90 links VEGF signaling to activation of eNOS and cytoskeletal rearrangements leading to EC migration. 4,19 -21 Next, we examined the effects of D88N Hsp90 on basal and VEGF-stimulated cell migration in BAECs transduced with Ad-GFP or Ad-D88N Hsp90. Infection with equal MOI of Ad-GFP or D88N Hsp90␤ had no effect on basal EC attachment and chemokinesis ( Figure 4A ), however D88N Hsp90␤ significantly reduced VEGF-stimulated migration of BAECs. Because there is evidence that growth factors may signal through Akt leading to EC migration, 19,21-23 we examined the effects of D88N Hsp90␤ on MLECs isolated from WT or Akt1 Ϫ/Ϫ mice. These isolated MLECs are transformed with the middle T antigen, which strongly activates the PI3 kinase-Akt pathway, thus, we could not examine VEGFstimulated migration. 22 As seen in Figure 4B , expression of D88N Hsp90 significantly suppressed serum stimulated migration in WT MLECs compared with Ad-GFP infected MLECs, similar to results in VEGF-stimulated BAECs. However, as shown in our previous study, 22 serum stimulated migration was reduced in Akt1 Ϫ/Ϫ MLECs compared with WT MLECs, and infection with Ad-D88N Hsp90 did not further attenuate serum induced migration in MLECs from Akt-1 Ϫ/Ϫ mice strongly supporting the idea that Hsp90 regulation of Akt1 is a major target for regulating endothelial cell migration.
D88N Hsp90␤ Inhibits VEGF-Stimulated Stress Fiber Formation and Rac Activation
Cell migration is associated with regulation of the actin cytoskeleton via activation of Rac GTPase. 24, 25 As shown previously, VEGF induces edge ruffling 26 and stress fiber formation in cultured endothelial cells. 19, 27 In quiescent BAECs infected with Ad-GFP or Ad-D88N Hsp90, F-actin was found mostly in peripheral membrane structures and unorganized fibers throughout the cell ( Figure 5A, top panel) . As expected, VEGF induced the formation of long condensed stress fibers ( Figure 5A, left panel, bottom) . However, VEGF-stimulated stress fiber formation was markedly attenuated in BAECs infected with Ad-D88N Hsp90 ( Figure 5A , right panel, bottom). Because Rac is an important regulator of stress fiber formation in endothelial cells, 24, 25 we examined VEGF stimulated Rac activation in BAECs infected with Ad-GFP or D88N Hsp90. As seen in Figure 5B , VEGF treatment resulted in Rac activation at 5 or 15 minutes in BAECs infected with Ad-GFP, an effect that was attenuated in cells infected with Ad D88N Hsp90. Figure 5C shows that treatment of BAECs with LY294002, PI-3 kinase inhibitor, blocked the VEGF-induced Rac activation at 5 or 15 minutes, whereas a Rac1 inhibitor 28 did not suppress VEGF-stimulated Akt activation in BAECs ( Figure 5D ) indicating that PI-3 kinase, but not Rac, is likely upstream of Akt. Consequently, both LY294002 and the Rac1 inhibitor suppressed VEGFstimulated BAEC migration, however they did not show any further inhibitory effects on the VEGF-induced migration in cells infected with Ad-D88N Hsp90 ( Figure 5E ). These data suggest that inhibitory effect of D88N Hsp90␤ on VEGFstimulated endothelial cell migration may be mediated by impaired Akt and Rac activation and subsequent formation of stress fibers.
Discussion
This paper characterizes a new reagent to test the cellular functions of Hsp90, namely an ATP-binding mutant that can dimerize with endogenous Hsp90 and serve as an inhibitor of several functions. Because the sites of ATP and GA binding are conserved and have been resolved cyrstallographically, we created an Hsp90 mutant by site-direct mutation of Asp88 (D88) to Asn (N88). Unlike WT Hsp90, recombinant D88N Hsp90 did not bind effectively to an ATP Sepharose column documenting D88 as a critical residue for ATP-binding ( Figure 1B) . The crystal structure of the N-terminal domain of the D79N mutant in yeast Hsp82 has verified that the loss of adenine nucleotide binding by the D79N mutant was attributable to the local changes in hydrogen bonding at the bottom of ADP/ATP-binding pocket, and not to gross misfolding of the protein as a result of the mutation. 15 Similar to previous reports, 6,7 D88N Hsp90␤ can form a homodimer with endogenous Hsp90␤ and heterodimer with endogenous Hsp90␣ (supplemental Figure IB) . These results suggest that this mutant D88N can effectively target the endogenous pools of Hsp90 and serve as a dominant-negative to disrupt the association of client proteins with Hsp90 similar to GA or 17-AAG, specific inhibitors.
Previous studies have shown that Akt and eNOS form a complex with Hsp90 in vitro and in vivo. 4,18,29 -31 Amino acid residues 327 to 340 of Hsp90␤ has been identified to be involved in the binding of Akt at the amino acid residues 229 to 309. 11 Inhibition of Akt-Hsp90 binding using Hsp90 deletion mutants led to the PP2A-mediated dephosphorylation and inactivation of Akt. Inhibition of Hsp90 with 17-AAG also results in the ubiquitination of Akt and its targeting to the proteasome. 8 Our previous report showed that Hsp90 associated with eNOS and enhanced the activation of eNOS. 4 In additional studies we have identified the M-region of Hsp90 that interacts with the amino terminus of eNOS and Akt, and have demonstrated that Hsp90 modulates Akt-driven phosphorylation of eNOS. 18 These results suggest that Hsp90 may function as a scaffold for eNOS and Akt and suggest that model that on activation of endothelial cells with VEGF, eNOS, and Akt are recruiting to an adjacent region on the same domain of Hsp90 to facilitate eNOS phosphorylation and enzyme activation. Supplemental Figure IB shows that eNOS and Akt formed complex with Hsp90␤ and Hsp90␣ and dominant-negative D88N Hsp90␤ inhibited the association of eNOS and Akt with Hsp90 and resulting in dephosphorylation of Akt (S473) and less phosphorylation of eNOS (S1179; Figure 2A and 2B) and NO release ( Figure 2D ). Consistent with a previous report, 11 the dephosphorylation of Akt and eNOS is mediated by PP2A because okadaic acid can rescue the dephosphorylation caused by D88N Hsp90␤ (Figure 3) . Collectively, these results demonstrate that dominantnegative Hsp90 can interrupt the association of Hsp90 complex with eNOS and Akt and disrupt the VEGF-stimulated phosphorylation signaling in endothelial cells.
We further investigated the effects of dominant-negative Hsp90 on other biological functions in endothelial cells. It has been reported that stimulation of ECs with VEGF leads to the activation of Akt by phosphorylation on threonine 308 and on serine 473ϫ3-phosphoinositide-dependent kinase-1 and -2, respectively. 32, 33 Besides mediating cell survival in ECs, Akt activates eNOS by phosphorylation on serine 1179, 34, 35 and phosphorylation of eNOS on serine 1179 enhances NO generation in a partially calcium-independent manner. Recent studies suggest that NO is an essential mediator of EC migration and VEGF-induced angiogenesis. Inhibition of eNOS suppresses the mitogenic and migratory effects of VEGF on ECs in vitro and the VEGF-induced angiogenic response in vivo. 36, 37 Moreover, it has been demonstrated that Akt mediates the VEGF-induced migration of ECs via activation of eNOS. 19, 23, 38 Here we demonstrate that inhibition of Akt and eNOS phosphorylation by dominant-negative Hsp90 subsequently reduces VEGF-stimulated migration of ECs ( Figure 4A ). However, this inhibitory effect was diminished by infection of MLEC Akt1
Ϫ/Ϫ cells with D88N Hsp90␤ ( Figure 4B ). Our previous study shows that Akt1 is the major isoform in ECs 22 important for VEGF-mediated angiogenesis in vivo and in vitro. These results support our hypothesis that Akt and eNOS binding to the scaffold of Hsp90 to facilitate eNOS phosphorylation and activation suggesting that Akt is a major modulator of actions of dominant-negative Hsp90.
Directed cell migration is associated with rearrangement of the actin cytoskeleton. As shown previously, VEGF induces edge ruffling and stress fiber formation in cultured ECs. Our previous results showed that VEGF-induced cell migration and F-actin rearrangement are dependent on Akt activity 19, 22 and that constitutively activated Akt is sufficient to cause cellular chemokinesis most likely because of its effects on stress fiber formation. 19 In the context of cell motility, the effectors of NO are not known. However, NO can influence the tractional forces in activated endothelial cells and influence remodeling of focal adhesions, perhaps by influencing tyrosine phosphorylation of focal adhesion kinase. 39 It has been demonstrated that Rac activation is required for haptotaxis on collagen-and VEGF-stimulated chemotaxis. Similar to VEGF, constitutively active Rac increased EC stress fiber formation and focal adhesions. 24, 25 VEGF treatment of Racactivated cells had no further effect on the actin cytoskeleton and focal adhesion. Transduction of dominant-negative Rac into ECs inhibited stress fiber and focal adhesion formation and suppressed VEGF-stimulated migration. 24, 25 These data indicate that Rac activation may be sufficient to activate the necessary downstream events in ECs required for VEGFinduced chemotaxis. In this study, we demonstrated that dominant-negative Hsp90␤ inhibits VEGF-induced stress fiber formation ( Figure 5A ) and Rac activation ( Figure 5B ) and VEGF-stimulated migration of ECs ( Figure 4A ). However, whether Rac activation and stress fiber formation are modulated by NO production is still unclear and is the focus of additional experiments. Our results also showed that Rac activation is dependent on the activation of PI3 kinase in BAECs because LY294002, a specific PI3 kinase inhibitor, can inhibit the Rac activation in BAECs ( Figure 5C ), but Rac inhibitor cannot block the activation of Akt mediated by PI3 kinase activation ( Figure 5D ). As expected, both LY294002 and Rac1 inhibitor can suppress VEGF-stimulated BAEC migration, however they did not show any further inhibitory effects on the VEGF-induced migration of BAECs infected with Ad-D88N Hsp90 ( Figure 5E ), suggesting that Hsp90 is critical for both pathways.
In summary, our data are the first to report a genetic approach in mammalian cells to demonstrate a critical role of Hsp90 in regulating EC functions including NO release and migration. We have shown that adenoviral expression of dominant-negative Hsp90 is a new tool to investigate the involvement of Hsp90 in a variety of cellular processes and may lead to the identification of new Hsp90 client proteins. The usage of dominant negative Hsp90␤ can complement the existing chemical approaches such as GA and 17-AAG to dissect the role of Hsp90 in mammalian cells.
